Amarantus Bioscience Holdings Inc (AMBS)

[mstrike]

Amarantus Establishes LymPro Research Collaboration With Boston University School of Medicine
Download PDF
SAN FRANCISCO, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it is establishing a research collaboration with researchers at Boston University School of Medicine (BUSM). The Company will work together with BUSM Professor of Neurology and Neurosurgery Dr. Robert Stern to evaluate the feasibility of using the LymPro Test ® as a blood based test to identify patients early in the disease process of the neurodegenerative diseases, chronic traumatic encephalopathy (CTE) and Alzheimer's disease (AD).

"We are pleased to be establishing this collaboration to evaluate the potential of LymPro in this emerging area of medical interest," said Gerald E. Commissiong, President and CEO of Amarantus. "While the research is early in nature, there is a strong scientific basis to believe that the cell cycle dysregulation that LymPro measures in Alzheimer's patients may have relevance to Traumatic Brain Injury and CTE. We are hopeful the information generated from this study will provide further insights for the field as we learn more about CTE."

Dr. Stern, who is the Clinical Core Director at the BU Alzheimer's Disease Center, has grant funding from the National Institutes of Health (NIH) to fund his work on developing methods of detecting and diagnosing CTE during life; this was the first grant for CTE ever funded by NIH (co-funded by the National Institute of Neurological Disorders and Stroke, the National Institute on Aging, and the National Institute of Child Health and Human Development). As part of the study, Stern and his colleagues have already examined over 70 former NFL players and 20 same age elite non-contact sport athletes.

"Cell cycle dysregulation is an emerging area of interest in Alzheimer's disease and Traumatic Brain Injury," said Dr. Stern. "We are hopeful the data gathered from this study will inform future studies into this important and emerging field of medical science."